Table.
Cohort Demographics and Clinical Characteristics Stratified by pSpA
| Variable, n (%) | Total (n = 1032) | pSpA (n = 192) | No SpA (n = 840) | P-value |
|---|---|---|---|---|
| IBD type | <.0001 | |||
| Crohn’s disease | 593 (57) | 138 (72) | 455 (54) | |
| Ulcerative colitis | 439 (43) | 54 (28) | 385 (46) | |
| Age, y, mean (± SD) | 47.3 (16.4) | 45.9 (15.5) | 47.6 (16.6) | .27 |
| Sex | .0002 | |||
| Male | 447 (43) | 60 (31) | 387 (46) | |
| Female | 585 (57) | 132 (69) | 453 (54) | |
| Smoking status | .19 | |||
| Current | 29 (3) | 9 (5) | 20 (2) | |
| Former | 192 (19) | 38 (20) | 154 (19) | |
| Never | 776 (78) | 139 (75) | 637 (79) | |
| Previous surgery | .38 | |||
| Yes | 349 (34) | 69 (37) | 280 (34) | |
| No | 667 (66) | 117 (63) | 550 (66) | |
| Crohn’s disease | ||||
| HBI <5 | 350 (60) | 60 (43) | 290 (65) | < .0001 |
| Mean BASDAI (± SD) | 2.6 (2.2) | .043 | ||
| HBI ≥5 | 235 (40) | 78 (57) | 157 (35) | |
| Mean BASDAI (± SD) | 3.5 (2.2) | |||
| SES-CD | .59 | |||
| Total SES-CD, ≤3 | 56 (25) | 15 (27) | 41 (24) | |
| Total SES-CD, >3 | 172 (75) | 40 (73) | 132 (76) | |
| Ulcerative colitis | ||||
| Total Mayo score, ≤2 | 245 (56) | 28 (53) | 217 (57) | .57 |
| Mean BASDAI (± SD) | 2.6 (2.4) | 164 (43) | .51 | |
| Total Mayo score, >2 | 189 (44) | 25 (47) | ||
| Mean BASDAI (± SD) | 2.1 (2.1) | |||
| Current treatment | ||||
| 5-ASA | 423 (41) | 76 (40) | 347 (41) | .66 |
| Immunomodulator | 104 (10) | 22 (11) | 82 (10) | .48 |
| Steroids/biologics | 453 (44) | 100 (52) | 353 (42) | .011 |
| Steroids | 103 (10) | 23 (12) | 80 (10) | .31 |
| Biologics | 392 (38) | 84 (44) | 308 (37) | .068 |
| Anti-TNFα | 211 (20) | 41 (21) | 170 (20) | .73 |
| Vedolizumab | 87 (8) | 15 (8) | 72 (9) | .73 |
| Ustekinumab | 101 (10) | 28 (15) | 73 (9) | .0013 |
| Current/previous biologic | 558 (54) | 120 (63) | 438 (52) | .0094 |
| Infliximab | .36 | |||
| Responder | 123 (46) | 24 (40) | 99 (47) | |
| PNR | 67 (25) | 14 (23) | 53 (25) | |
| SNR | 79 (29) | 22 (37) | 57 (27) | |
| Adalimumab | < .0001 | |||
| Responder | 61 (30) | 8 (16) | 53 (35) | |
| PNR | 88 (44) | 17 (35) | 71 (46) | |
| SNR | 53 (26) | 24 (49) | 29 (19) | |
| Vedolizumab | .27 | |||
| Responder | 56 (46) | 9 (41) | 47 (47) | |
| PNR | 45 (37) | 11 (50) | 34 (34) | |
| SNR | 22 (18) | 2 (9) | 20 (20) | |
| Ustekinumab | .69 | |||
| Responder | 58 (59) | 17 (65) | 41 (57) | |
| PNR | 29 (30) | 6 (23) | 23 (32) | |
| SNR | 11 (11) | 3 (12) | 8 (11) |
Subject number and percentage are shown. Mann-Whitney test and Pearson’s chi-squared test were used to determine the P-value for differences between subjects with and without SpA.
PNR, primary nonresponse; SNR, secondary nonresponse.